31 related articles for article (PubMed ID: 38442670)
1. Activation of adenosine A
Carlin JL; Jain S; Duroux R; Suresh RR; Xiao C; Auchampach JA; Jacobson KA; Gavrilova O; Reitman ML
Neuropharmacology; 2018 Sep; 139():268-278. PubMed ID: 29548686
[TBL] [Abstract][Full Text] [Related]
2. Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors.
Webb TR; Lvovskiy D; Kim SA; Ji Xd; Melman N; Linden J; Jacobson KA
Bioorg Med Chem; 2003 Jan; 11(1):77-85. PubMed ID: 12467710
[TBL] [Abstract][Full Text] [Related]
3. Structural Modification and Biological Evaluation of 2,8-Disubstituted Adenine and Its Nucleosides as A
Kim G; Jarhad DB; Lee G; Kim G; Hou X; Yu J; Lee CS; Warnick E; Gao ZG; Ahn SY; Kwak D; Park K; Lee SD; Park TU; Jung SY; Lee JH; Choi JR; Kim M; Kim D; Kim B; Jacobson KA; Jeong LS
J Med Chem; 2024 Jun; ():. PubMed ID: 38845345
[TBL] [Abstract][Full Text] [Related]
4. A
Tay AHM; Prieto-Díaz R; Neo S; Tong L; Chen X; Carannante V; Önfelt B; Hartman J; Haglund F; Majellaro M; Azuaje J; Garcia-Mera X; Brea JM; Loza MI; Jespers W; Gutierrez-de-Teran H; Sotelo E; Lundqvist A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580926
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Effect of Halogenation in a Series of Potent and Selective A
Prieto-Díaz R; González-Gómez M; Fojo-Carballo H; Azuaje J; El Maatougui A; Majellaro M; Loza MI; Brea J; Fernández-Dueñas V; Paleo MR; Díaz-Holguín A; Garcia-Pinel B; Mallo-Abreu A; Estévez JC; Andújar-Arias A; García-Mera X; Gomez-Tourino I; Ciruela F; Salas CO; Gutiérrez-de-Terán H; Sotelo E
J Med Chem; 2023 Jan; 66(1):890-912. PubMed ID: 36517209
[TBL] [Abstract][Full Text] [Related]
6. Identification of V6.51L as a selectivity hotspot in stereoselective A
Wang X; Jespers W; Prieto-Díaz R; Majellaro M; IJzerman AP; van Westen GJP; Sotelo E; Heitman LH; Gutiérrez-de-Terán H
Sci Rep; 2021 Jul; 11(1):14171. PubMed ID: 34238993
[TBL] [Abstract][Full Text] [Related]
7. Kinetic profiling and functional characterization of 8-phenylxanthine derivatives as A
Vlachodimou A; de Vries H; Pasoli M; Goudswaard M; Kim SA; Kim YC; Scortichini M; Marshall M; Linden J; Heitman LH; Jacobson KA; IJzerman AP
Biochem Pharmacol; 2022 Jun; 200():115027. PubMed ID: 35395239
[TBL] [Abstract][Full Text] [Related]
8. Irreversible Antagonists for the Adenosine A
Temirak A; Schlegel JG; Voss JH; Vaaßen VJ; Vielmuth C; Claff T; Müller CE
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744918
[TBL] [Abstract][Full Text] [Related]
9. Exploring Biginelli-based scaffolds as A
Prieto-Díaz R; Fojo-Carballo H; Majellaro M; Tandarić T; Azuaje J; Brea J; Loza MI; Barbazán J; Salort G; Chotalia M; Rodríguez-Pampín I; Mallo-Abreu A; Rita Paleo M; García-Mera X; Ciruela F; Gutiérrez-de-Terán H; Sotelo E
Biomed Pharmacother; 2024 Apr; 173():116345. PubMed ID: 38442670
[TBL] [Abstract][Full Text] [Related]
10. A
Gao ZG; Jacobson KA
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627281
[TBL] [Abstract][Full Text] [Related]
11. The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases.
Eisenstein A; Patterson S; Ravid K
J Cell Physiol; 2015 Dec; 230(12):2891-7. PubMed ID: 25975415
[TBL] [Abstract][Full Text] [Related]
12. Adenosine receptors and diabetes: Focus on the A(2B) adenosine receptor subtype.
Merighi S; Borea PA; Gessi S
Pharmacol Res; 2015 Sep; 99():229-36. PubMed ID: 26142494
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
